生物制剂治疗类风湿关节炎降低新发慢性肾脏病风险
该队列研究纳入20,757例美国退伍军人类风湿关节炎患者,基线eGFR≥60 mL/min/1.73m2,随访至2013年。倾向性匹配分析显示,使用生物制剂与新发CKD风险降低及eGFR下降减缓独立相关。
要点
- 生物制剂治疗与新发CKD(eGFR<45)风险降低相关(HR 0.71)。
- 生物制剂治疗与eGFR快速下降风险降低相关(OR 0.67)。
- 使用生物制剂后eGFR下降速度显著减缓。
核心结论
- 生物制剂治疗与类风湿关节炎患者新发CKD及进行性eGFR下降风险降低独立相关。
研究设计与样本
- 回顾性队列研究,纳入20,757例美国退伍军人类风湿关节炎患者,基线eGFR≥60 mL/min/1.73m2,2004年10月至2006年9月招募,随访至2013年。
主要发现
- 倾向性匹配队列中,使用生物制剂者新发CKD(eGFR<60且较基线下降≥25%)的HR为0.95(95%CI 0.82-1.10),eGFR<45的HR为0.71(95%CI 0.53-0.94)。
- eGFR斜率<-3 mL/min/1.73m2/年的OR为0.67(95%CI 0.58-0.79),≥0 mL/min/1.73m2/年的OR为0.76(95%CI 0.69-0.83),均以-3至<0为参照。
- 使用生物制剂后eGFR下降速度从-1.0减缓至-0.4 mL/min/1.73m2/年。
临床怎么用
- 对于类风湿关节炎患者,使用生物制剂可能有助于降低新发CKD和eGFR进行性下降的风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rheumatoid arthritis is associated with reduced kidney function, possibly due to chronic inflammation or the use of nephrotoxic therapies. However, little is known about the effects of using the newer novel non-nephrotoxic biologic agents on the risk of incident chronic kidney disease (CKD). To study this we used a cohort of 20,757 United States veterans diagnosed with rheumatoid arthritis with an estimated glomerular filtration rate (eGFR) of 60 mL/min/1.73m2 or more, recruited between October 2004 and September 2006, and followed through 2013. The associations of biologic use with incident CKD (eGFR under 60 with a decrease of at least 25% from baseline, and eGFR under 45 mL/min/1.73m2) and change in eGFR (<-3, -3 to <0 [reference], and ≥0 mL/min/1.73m2/year) were examined in propensity-matched patients based on their likelihood to initiate biologic treatment, using Cox models and multinomial logistic regression models, respectively. Among 20,757 patients, 4,617 started biologic therapy. In the propensity-matched cohort, patients treated (versus not treated) with biologic agents had a lower risk of incident CKD (hazard ratios 0.95, 95% confidence interval [0.82-1.10] and 0.71 [0.53-0.94] for decrease in eGFR under 60 and under 45 mL/min/1.73m2, respectively) and progressive eGFR decline (multinomial odds ratios [95% CI] for eGFR slopes <-3 and ≥0 [versus -3 to <0] mL/min/1.73m2/year, 0.67 [0.58-0.79] and 0.76 [0.69-0.83], respectively). A significant deceleration of eGFR decline was also observed after biologic administration in patients treated with biologics (-1.0 versus -0.4 [mL/min/1.73m2/year] before and after biologic use). Thus, biologic agent administration was independently associated with lower risk of incident CKD and progressive eGFR decline.
引用
- Sumida K, Molnar MZ, Potukuchi PK, et al. Treatment of rheumatoid arthritis with biologic agents lowers the risk of incident chronic kidney disease. Kidney Int. 2018. PMID: 29409725. doi:10.1016/j.kint.2017.11.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。